<DOC>
	<DOC>NCT01323153</DOC>
	<brief_summary>This double-blind, randomized, placebo-controlled, multi-center study will evaluate the safety and efficacy of dalcetrapib in patients hospitalized for an acute coronary syndrome (ACS). Treatment will be initiated within 1 week after the ACS. Patients will be randomized to receive dalcetrapib 600 mg as daily oral doses or matching placebo. The anticipated time on study treatment is 20 weeks.</brief_summary>
	<brief_title>A Study of Dalcetrapib in Patients Hospitalized For An Acute Coronary Syndrome (Dal-ACUTE)</brief_title>
	<detailed_description />
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Dalcetrapib</mesh_term>
	<criteria>Adult patients, &gt;/=45 years of age Patients admitted to the hospital for acute coronary syndrome (ACS) Patients receiving guidelinebased medical and dietary management of dyslipidemia Symptomatic congestive heart failure (NYHA Class III or IV) Clinically significant heart disease requiring coronary artery bypass grafting, cardiac transplantation, surgical valve repair/replacement during the study Uncontrolled hypertension Uncontrolled diabetes Severe anemia Concomitant treatment with any other drug raising highdensity lipoprotein C (HDLC; eg niacin, fibrates)</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>